174 related articles for article (PubMed ID: 28178124)
1. Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report.
Giannetta E; Isidori AM; Durante C; Di Gioia C; Longo F; Tombolini V; Bulzonetti N; Graziadio C; Pofi R; Gianfrilli D; Verrienti A; Carletti R; Filetti S; Lenzi A; Baroli A
Medicine (Baltimore); 2017 Feb; 96(6):e5621. PubMed ID: 28178124
[TBL] [Abstract][Full Text] [Related]
2. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A
Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510
[TBL] [Abstract][Full Text] [Related]
3. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic thyroid carcinoma with rapid thyrotoxicosis - a case report and the literature review.
Daroszewski J; Paczkowska K; Jawiarczyk-Przybyłowska A; Bolanowski M; Jeleń M
Endokrynol Pol; 2018; 69(1):28-31. PubMed ID: 29319130
[TBL] [Abstract][Full Text] [Related]
5. Complete response to weekly carboplatin-docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer.
Koussis H; Giorgi CA; Di Liso E; Carlucci MC; Fassina A; Marioni G; Conte PF
Am J Otolaryngol; 2015; 36(2):268-72. PubMed ID: 25681954
[TBL] [Abstract][Full Text] [Related]
6. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
7. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.
Poisson T; Deandreis D; Leboulleux S; Bidault F; Bonniaud G; Baillot S; Aupérin A; Al Ghuzlan A; Travagli JP; Lumbroso J; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2277-85. PubMed ID: 20694463
[TBL] [Abstract][Full Text] [Related]
8. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer.
Levy A; Leboulleux S; Lepoutre-Lussey C; Baudin E; Ghuzlan AA; Hartl D; Deutsch E; Deandreis D; Lumbroso J; Tao Y; Schlumberger M; Blanchard P
Oral Oncol; 2015 Apr; 51(4):370-5. PubMed ID: 25595614
[TBL] [Abstract][Full Text] [Related]
9. A bone metastases model of anaplastic thyroid carcinoma in athymic nude mice.
Zhang L; Wang H; Liang S; Ma C
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):351-6. PubMed ID: 25069676
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
11. Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.
Kim SK; So Y; Chung HW; Yoo YB; Park KS; Hwang TS; Kim B; Lee WW
Cancer Med; 2016 Oct; 5(10):2756-2762. PubMed ID: 27539659
[TBL] [Abstract][Full Text] [Related]
12. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
13. Foscarnet reduces FGF2-induced proliferation of human umbilical vein endothelial cells and has antineoplastic activity against human anaplastic thyroid carcinoma cells.
Rose K
Biomed Pharmacother; 2013 Feb; 67(1):53-7. PubMed ID: 23228448
[TBL] [Abstract][Full Text] [Related]
14. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report.
Goh D; Lim KH; Sudirman SRB; Ang MK; Chua MLK; Lim CM
Chin Clin Oncol; 2023 Oct; 12(5):57. PubMed ID: 37964542
[TBL] [Abstract][Full Text] [Related]
15. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma.
Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Kasperbauer JL; Reading CC; Hay ID; Lowe VJ
Thyroid; 2008 Jul; 18(7):713-9. PubMed ID: 18630999
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.
Kim BS; Kim SJ; Kim IJ; Pak K; Kim K
Thyroid; 2012 Jul; 22(7):725-9. PubMed ID: 22524470
[TBL] [Abstract][Full Text] [Related]
18. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
20. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
